Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003961 · ClinicalTrials.gov registry record · Phase 2
Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003961 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
The verdict
NCT00003961, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase II trial to study the effectiveness of sargramostim after bone marrow transplantation in treating patients who have myelodysplastic syndrome.
Interventions
- BIOLOGICAL sargramostim
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-04 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003961
The ClinicalTrials.gov registry entry for NCT00003961 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sargramostim is the first listed.
NCT00003961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003961 about?
NCT00003961 is a clinical study titled "Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome". RATIONALE: Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase II trial to study the effectiveness of sargramostim after bone marrow transplantation in treating patients who have myelodysplastic syndrome.
What is the current status of trial NCT00003961?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-04. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00003961?
The interventions under investigation include: sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003961?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.